๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Zhengzhou
Clinical trial register · China

Clinical Trials in Zhengzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Henan Cancer Hospital72 The First Affiliated Hospital of Zhengzhou University39 Merck Sharp & Dohme LLC27 AbbVie21 Novartis Pharmaceuticals20
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Zhengzhou

921 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
PDL1/TGFฮฒ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer
NCT07294664Advanced Gastric Cancer, SHR1701
The First Affiliated Hospital of Zhengzhou University
Phase 2
78
Zhengzhou
2025-06-15
Not yet open
Clinical Study on Improving Exercise Capacity in Chronic Obstructive Pulmonary Disease Through Smart IoT-Remote Home Breathing Guidance
NCT06963333Chronic Obstructive Pulmonary Disease
Henan University of Traditional Chinese Medicine
Not applicable
548
Zhengzhou
2025-06-15
Recruiting
A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China
NCT06933472Hyperphosphatemia, Chronic Kidney Disease, Receiving Dialysis, ESRD (End-Stage Renal Disease), Dialysis
Alebund Pharmaceuticals
Phase 3
264
Beijing, Xiamen, Zhengzhou, Wuhan, Changsha, Nanjing, Nantong, Wuxi
2025-06-13
Recruiting
A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China
NCT06931691Paroxysmal Nocturnal Hemoglobinuria
Novartis Pharmaceuticals
Observational
80
Hefei, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Nantong, Nanchang, Changchun
2025-06-10
Recruiting
Lactobacillus Plantarum and Hormonal Regulation in Obese Women
NCT06987279Obesity, Women
Wecare Probiotics Co., Ltd.
Not applicable
100
Zhengzhou
2025-06-10
Recruiting
A Study to Evaluate the Safety and Efficacy of PN20 in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure
NCT07446491Thrombocytopenia Associated With Chronic Liver Disease
Chongqing Peg-Bio Biopharm Co., Ltd.
Phase 1/2
54
Beijing, Chongqing, Guangzhou, Zhengzhou, Zhenjiang, Changchun, Chaozhou, Qingdao
2025-06-06
Recruiting
Tracjectories and Predictors of Chemotherapy Induced Peripheral Neuropathy in Children With Acute Lymphoblastic Leukemia
NCT07326930Acute Lymphoblastic Leukemia ALL
The Hong Kong Polytechnic University
Observational
173
Zhengzhou, Shanghai, Shenzhen
2025-06-02
Active, closed
Spatiotemporal Dynamics and Prognostic Value of the 18F-FDG PET Neuro-Metabolic Network
NCT07203495Lung Diseases, Endocrine Diseases, Gastrointestinal Diseases
The First Affiliated Hospital of Zhengzhou University
Observational
200
Zhengzhou
2025-06-01
Recruiting
Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC
NCT06896422Non-Small Cell Lung Cancer, Chemotherapy, PD1 Antibody, Glutathione
The First Affiliated Hospital of Zhengzhou University
Phase 1
80
Zhengzhou
2025-06-01
Not yet open
Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma
NCT06956092B Cell Lymphoma (BCL)
Zhengzhou University
Phase 4
40
Zhengzhou
2025-05-30
Recruiting
JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
NCT06954467Hepatocellular Carcinoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
72
Hefei, Beijing, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Shanghai
2025-05-29
Recruiting
Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)
NCT06780098Lung Neoplasm
Merck Sharp & Dohme LLC
Phase 2
144
Beijing, Chongqing, Fuzhou, Nanning, Zhengzhou, Nanjing, Shanghai
2025-05-28
Recruiting
Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Esophageal Carcinoma
NCT06979869Esophageal Cancer
Xijing Hospital
Observational
300
Wuwei, Shantou, Zhaoqing, Zhengzhou, Xi'an, Yanโ€™an, Taiyuan, Chengdu
2025-05-26
Recruiting
A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TQB3019 Capsule in Subjects With Advanced Malignant Tumors
NCT06943677Advanced Malignant Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
80
Beijing, Guangzhou, Zhengzhou, Nanjing, Nanchang, Xi'an, Heze, Jinan
2025-05-26
Recruiting
A Clinical Trial of Rabies Vaccine๏ผˆHuman Diploid Cell๏ผ‰for Human Use,Freeze-dried
NCT07021703Rabies
Ningbo Rongan Biological Pharmaceutical Co., Ltd.
Phase 1
60
Zhengzhou
2025-05-23
Recruiting
The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies
NCT07002112Relapsed/Refractory B-cell Malignancies
The First Affiliated Hospital with Nanjing Medical University
Phase 1
30
Hefei, Beijing, Shijiazhuang, Zhengzhou, Wuhan, Nanjing
2025-05-23
Recruiting
A Phase I Study of SIM0686 in Participants With Locally Advanced/Metastatic Solid Tumors
NCT07050459Locally Advanced Solid Tumors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
220
Beijing, Haerbin, Zhengzhou, Changsha, Nanjing, Jinan, Shanghai, Chengdu
2025-05-20
Recruiting
Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
NCT06830798Delayed Graft Function, DGF, Kidney Transplant
Alexion Pharmaceuticals, Inc.
Phase 3
450
Guangzhou, Hangzhou, Hengyang, Nanning, Shenzhen, Taiyuan, Tianjin, Zhengzhou
2025-05-19
Recruiting
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06925737Prostate Cancer, Prostatic Neoplasms
Merck Sharp & Dohme LLC
Phase 3
1,440
Beijing, Chongqing, Fuzhou, Guangzhou, Zhuhai, Nanning, Zhengzhou, Wuhan
2025-05-13
Recruiting
A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)
NCT06929299Primary Immune Thrombocytopenia (ITP)
Jiangsu BioJeTay Biotechnology Co., Ltd.
Phase 1/2
56
Bengbu, Beijing, Tangshan, Zhengzhou, Nanchang, Xiโ€™an, Tianjin
2025-05-12
Recruiting
Crisugabalin for Radiotherapy-Related Neuropathic Pain
NCT06766916Neuropathic Pain
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
172
Fuzhou, Guangzhou, Zhongshan, Nanning, Zhengzhou, Changsha
2025-05-07
Recruiting
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
NCT06892548Advanced Lung Cancer
BioNTech SE
Phase 1/2
594
Hefei, Beijing, Fuzhou, Nanning, Weihui, Zhengzhou, Jingzhou, Xiangyang
2025-05-02
Recruiting
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
NCT06916806Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis
AstraZeneca
Phase 1
72
Beijing, Shanghai, Wuhan, Zhengzhou
2025-05-01
Not yet open
Clinical Trial of HRS-4642 Plus SHR-A2102 in Patients With Advanced Solid Tumors
NCT06955390Solid Tumors
Henan Cancer Hospital
Phase 1/2
32
Zhengzhou
2025-05-01
Recruiting
Reinforcement Learned Automatic Anesthesia System During Painless Gastrointestinal Endoscopy
NCT06857344Anesthesia Induction
Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd.
Not applicable
164
Anxi, Jinjiang, Xinzheng, Zhengzhou
2025-05-01
Not yet open
The Efficacy of Oral Cryotherapy in Preventing TROP2-ADC-Induced Oral Mucositis in Patients With Advanced Breast Cancer
NCT06934733Advanced or Metastatic Breast Cancer
Henan Cancer Hospital
Not applicable
124
Zhengzhou
2025-05
Recruiting
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
NCT06862869Carcinoma, Non-Small-Cell Lung
Hoffmann-La Roche
Observational
800
Zhanjiang, Guangzhou, Kaifeng, Zhengzhou, รœrรผmqi, Beijing, Changsha, Changzhou
2025-04-30
Recruiting
A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer
NCT06623136Non-Small Cell Lung Cancer
Elpiscience (Suzhou) Biopharma, Ltd.
Phase 2
40
Beijing, Zhengzhou, Nanchang, Changchun, Jinan, Luoyang, Taiyuan, Taizhou
2025-04-30
Recruiting
The Efficacy and Safety of Inpegsomatropin Injection in Children With Idiopathic Short Stature
NCT06927310Idiopathic Short Stature
Xiamen Amoytop Biotech Co., Ltd.
Phase 3
300
Hefei, Beijing, Chongqing, Xiamen, Lanzhou, Guangzhou, Zhengzhou, Wuhan
2025-04-28
Recruiting
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
NCT06927180Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Henan Cancer Hospital
Phase 2
180
Zhengzhou
2025-04-16
Recruiting
Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer
NCT06860529HR+/HER2- Breast Cancer
Henan Cancer Hospital
Phase 2
357
Zhengzhou
2025-04-15
Active, closed
Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere
NCT06900543Unresectable Hepatocellular Carcinoma
Chengdu New Radiomedicine Technology Co. LTD.
Phase 3
108
Fuzhou, Guangzhou, Zhengzhou, Wuhan, Nanjing, Shenyang, Xiโ€™an, Chengdu
2025-04-15
Recruiting
Evaluation of Clinical Effect of Acupuncture on Acute Exacerbation of Bronchial Asthma
NCT07632352Bronchial Asthma
Henan University of Traditional Chinese Medicine
Not applicable
72
Zhengzhou
2025-04-15
Recruiting
Phase III Clinical Trial Evaluating the Resection Efficacy of 5-Aminolevulinic Acid Hydrochloride (5-ALA HCl) Fluorescence-Guided Microsurgery Versus Conventional White Light Microsurgery in Patients With Malignant Glioma (WHO Grade 3/4)
NCT061604925-aminolevulinic Acid, Fluorescence-guided Resection
Lee's Pharmaceutical Limited
Phase 3
144
Guangzhou, Zhengzhou
2025-04-14
Recruiting
Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ยฑ Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C
NCT06821503Advanced Pancreatic Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
72
Beijing, Chongqing, Harbin, Zhengzhou, Wuhan, Nanjing, Nanchang, Shenyang
2025-04-11
Recruiting
An Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate to Severely Active Ulcerative Colitis (UC)
NCT06838845Ulcerative Colitis
AbbVie
Observational
80
Guangzhou, Zhengzhou
2025-04-09
Recruiting
Efficacy and Safety of Catheter abLation in patiEnts With seVere mitrAl regurgiTation and pErsistent Atrial Fibrillation: a Randomized Controlled Trial
NCT06883864Atrial Fibrillation (AF), Catheter Ablation, Atrial Functional Mitral Regurgitation
Beijing Anzhen Hospital
Not applicable
146
Hefei, Beijing, Xiamen, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan
2025-04-08
Recruiting
Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors
NCT06658951HER2-positive Advanced Malignant Solid Tumors
UTC Therapeutics Inc.
Not applicable
30
Zhengzhou
2025-04-03
Recruiting
A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR-sensitive Mutations and Brain Metastasis
NCT06945705NSCLC
Henan Cancer Hospital
Phase 2
146
Zhengzhou
2025-04-02
Recruiting
Icaritin in Combination With AG in Patients With Previously Untreated Advanced Pancreatic Ductal Adenocarcinoma
NCT06825546Advanced Pancreatic Ductal Adenocarcinoma
Sir Run Run Shaw Hospital
Phase 2
70
Guangzhou, Zhengzhou, Wuhan, Changsha, Hangzhou, Wenzhou
2025-04-01
Not yet open
The Severity Assessment Model for AECOPD With Combination of Disease and Syndrome
NCT06918353Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Henan University of Traditional Chinese Medicine
Observational
1,500
Zhengzhou
2025-04-01
Recruiting
Allogeneic ฮณฮดT Cells in Glioblastoma
NCT07144735Glioblastoma (GBM), Glioblastoma Multiforme (GBM)
Peking University Third Hospital
Not applicable
18
Beijing, Zhengzhou
2025-04-01
Not yet open
A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors
NCT06947226Solid Tumors
Mabwell (Shanghai) Bioscience Co., Ltd.
Phase 1/2
188
Zhengzhou
2025-04
Not yet open
Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain
NCT06897917Opioid-Induced Constipation, Pain Cancer
Henan Cancer Hospital
Phase 4
203
Zhengzhou
2025-04
Recruiting
To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
NCT06833983Hemophilia A
Gritgen Therapeutics Co., Ltd.
Phase 3
50
Hefei, Beijing, Lanzhou, Guangzhou, Tangshan, Zhengzhou, Wuhan, Changsha
2025-03-31
Not yet open
Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
NCT06885840Non-Small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd.
Phase 2
100
Hefei, Lanzhou, Dongguan, Foshan, Guangzhou, Baoding, Harbin, Zhengzhou
2025-03-31
Active, closed
Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients
NCT06922045Hemophilia
Jiangsu BioJeTay Biotechnology Co., Ltd.
Phase 3
40
Hefei, Lanzhou, Guangzhou, Shenzhen, Nanning, Tangshan, Harbin, Zhengzhou
2025-03-26
Recruiting
Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma
NCT06932068HER2 Negative, Low PD-L1 Expressing, Unresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
Qilu Hospital of Shandong University
Phase 2
77
Zhengzhou, Binzhou, Dezhou, Dongying, Jinan, Jining, Liaocheng, Linyi
2025-03-26
Recruiting
This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile.
NCT06756451Hematologic Malignancies
Nanjing RegeneCore Biotech Co., Ltd.
Phase 1
71
Hefei, Guangzhou, Shenzhen, Guilin, Nanning, Baoding, Tangshan, Zhengzhou
2025-03-25
Recruiting
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL
NCT06559345Acute Lymphoblastic Leukemia, Pediatric
The First Affiliated Hospital of Zhengzhou University
Phase 2
276
Zhengzhou
2025-03-17
Recruiting
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
NCT06841354Triple Negative Breast Neoplasms
Merck Sharp & Dohme LLC
Phase 3
1,000
Bengbu, Chongqing, Xiamen, Guangzhou, Nanning, Zhengzhou, Wuhan, Xiangyang
2025-03-16
Not yet open
Study on the Enhancement of Intestinal and Immune Functions Through Probiotic Intervention
NCT06863415Healthy
Wecare Probiotics Co., Ltd.
Not applicable
90
Zhengzhou
2025-03-15
Recruiting
A Single-Arm, Phase II Clinical Trail of Cadonilimab Combined With Chemoradiotherapy in Oligometastatic Stage IVB Cervical Cancer
NCT06998394Cervical Cancer Stage IV
Xiangbo Wan
Phase 2
30
Zhengzhou
2025-03-12
Recruiting
Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
NCT06854445Diffuse Large Cell B-lymphoma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 2
55
Wuhu, Xiamen, Lanzhou, Guangzhou, Nanning, Shijiazhuang, Harbin, Zhengzhou
2025-03-12
Recruiting
A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer
NCT06792695Metastatic Colorectal Cancer
AstraZeneca
Phase 2
80
Beijing, Chengdu, Harbin, Shanghai, Wuhan, Zhengzhou
2025-03-12
Not yet open
Investigating the Efficacy of Probiotics in Enhancing Gastrointestinal and Immunological Health
NCT06886724Intestinal and Lmmune Function Lmproved
Wecare Probiotics Co., Ltd.
Not applicable
40
Zhengzhou
2025-03-10
Recruiting
Neoadjuvant Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer
NCT07104149Female, Age โ‰ฅ 18 Years Old, No Previous Systemic Treatment for the Current Disease, Including Surgery, Antitumor Radiochemotherapy/Immunotherapy, ECOG Score of 0-1, Histologically Confirmed Cervical Cancer, FIGO Stage IB3, IIA2, IIB, IIIC, and Assessed by the Researcher as Resectable Lesion
The First Affiliated Hospital of Zhengzhou University
Phase 2
29
Zhengzhou
2025-03-10
Not yet open
Research on the Improvement of Intestinal and Immune Functions by Probiotics
NCT06873425Intestinal Health
Wecare Probiotics Co., Ltd.
Not applicable
40
Zhengzhou
2025-03-10
Not yet open
Research on the Role of Probiotics in Human Intestinal Health
NCT06886711Intestinal Microbiota
Wecare Probiotics Co., Ltd.
Not applicable
45
Zhengzhou
2025-03-10
Active, closed
Prospective Phase II Clinical Study of Neoadjuvant Chemoradiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
NCT06888531Esophageal Malignant Neoplasm Primary
Henan Cancer Hospital
Phase 2
30
Zhengzhou
2025-03-08
Recruiting
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
NCT06772623Non Small Cell Lung Carcinoma
AbbVie
Phase 1/2
252
Beijing, Fuzhou, Liuzhou, Zhengzhou, Wuhan, Changsha, Nanjing, Nanchang
2025-03-06
Recruiting
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
NCT06742996Mantle Cell Lymphoma, B Cell Lymphoma
BeOne Medicines
Phase 3
300
Beijing, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing, Xuzhou
2025-03-05
Recruiting
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of Haplo-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL
NCT06564545Acute Lymphoblastic Leukemia, Adult
The First Affiliated Hospital of Zhengzhou University
Phase 2
276
Zhengzhou
2025-03-01
Recruiting
Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer
NCT06521866Advanced Colorectal Carcinoma, Immunotherapy
Fudan University
Phase 2
208
Fuzhou, Xiamen, Lanzhou, Zhengzhou, Huaian, Jinan, Taian, Shanghai
2025-03-01
Recruiting
A Multicenter Prospective Randomized Controlled Clinical Trial Comparing Constant (5%) Versus Sequential (5%-2%) Oxygen Concentration Embryo Culture Protocols in Assisted Reproductive Technology
NCT07050537Fertility Issues, Blastocyst IVF, Embryo Culture
The First Affiliated Hospital with Nanjing Medical University
Not applicable
980
Zhengzhou, Changzhou, Nanjing, Suzhou, Xiโ€™an
2025-03-01
Recruiting
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL
NCT06564493Acute Lymphoblastic Leukemia, Pediatric
The First Affiliated Hospital of Zhengzhou University
Phase 2
170
Zhengzhou
2025-03-01
Active, closed
A Clinical Study of Furmonertinib in the Treatment of EGFR-Mutated NSCLC With Leptomeningeal Metastases
NCT06926803Lung Cancer (NSCLC), Leptomeningeal Cancer
Qiming Wang
Observational
500
Zhengzhou
2025-03-01
Not yet open
Effectiveness of Ginkgo Diterpene Lactone Meglumine in Acute Ischemic Stroke
NCT06861426Acute Ischemic Stroke
Ying Gao
Observational
4,460
Lanzhou, Harbin, Zhengzhou, Nanjing, Xuzhou, Changchun, Jining, Xian
2025-03-01
Recruiting
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Adult ALL
NCT06557161Acute Lymphoblastic Leukemia, Adult
The First Affiliated Hospital of Zhengzhou University
Phase 2
170
Zhengzhou
2025-03-01
Recruiting
JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia
NCT06890065B Acute Lymphoblastic Leukemia, B-Non Hodgkin Lymphoma
Shenzhen Genocury Biotech Co., Ltd.
Not applicable
20
Zhengzhou
2025-03-01
Active, closed
Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple Myeloma
NCT06924424Multiple Myeloma, Neoplasms
Peking University People's Hospital
Not applicable
105
Beijing, Zhengzhou
2025-03-01
Not yet open
A Prospective, Multicenter, Phase II Clinical Study on the Treatment of Unresectable Advanced HCC with DEB-TACE Combined with SALOX-HAIC
NCT06823050Hepatocellular Carcinoma
Xuhua Duan
Observational
59
Dengzhou, Jiaozuo, Kaifeng, Luoyang, Shangqiu, Zhengzhou, Zhoukou
2025-03-01
Recruiting
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06722235Immune Thrombocytopenic Purpura (ITP)
Takeda
Phase 3
171
Beijing, Guangzhou, Nanning, Shijiazhuang, Wuhan, Zhengzhou, Suzhou, Nanchang
2025-02-27
Recruiting
To Evaluate the Safety and Efficacy of a Single-Use IVUS Ablation for Primary Hypertension
NCT07051811Essential Hypertension
Lepu Medical Technology (Beijing) Co., Ltd.
Not applicable
213
Beijing, Chongqing, Xiamen, Lanzhou, Shenzhen, Zhengzhou, Hohhot, Yinchuan
2025-02-25
Recruiting
Organoid-guided Personalized Treatment of Pleural Effusion
NCT06959173Lung Cancer
Henan Cancer Hospital
Observational
20
Zhengzhou
2025-02-21
Recruiting
Clinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment of ES-SCLC
NCT07244016Extensive-stage Small-cell Lung Cancer
Henan Cancer Hospital
Observational
40
Zhengzhou
2025-02-20
Active, closed
Phase IV Study to Evaluate the Efficacy and Safety of Fang Le Shu Compared to Guo Na Fen for Controlled Ovarian Stimulation in Infertile Women Undergoing in Vitro Fertilization-embryo Transfer (IVF-ET).
NCT06921395Female Infertility
LG Chem
Phase 4
248
Zhengzhou
2025-02-15
Active, closed
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
NCT06619236Platinum-resistant Ovarian Cancer
Genmab
Phase 3
530
Guangzhou, Xi'an, Changchun, Hanzhou, Shanghai, Tianjin, Zhengzhou
2025-02-07
Recruiting
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
NCT06744920Generalized Myasthenia Gravis
Novartis Pharmaceuticals
Phase 3
180
Hefei, Guangzhou, Shijiazhuang, Zhengzhou, Wuhan, Wuxi, Changchun, Beijing
2025-02-07
Recruiting
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
NCT06756932Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
BeOne Medicines
Phase 1
120
Guangzhou, Zhengzhou, Shanghai, Tianjin, Hangzhou
2025-02-04
Recruiting
Chronic Airway Disease and Multimorbidity Cohort
NCT06798077Chronic Obstructive Pulmonary Disease (COPD), Asthma, Bronchiectasis
China-Japan Friendship Hospital
Observational
2,000
Beijing, Guangzhou, Zhengzhou, Wuhan, Changsha, Shenyang, Xi'an, Shanghai
2025-02-01
Not yet open
Real-world Study of Sunvozertinib Treatment in Advanced EGFR-Mutant NSCLC After EGFR-TKI Treatment Failure
NCT06786208Non Small Cell Lung Cancer
Henan Cancer Hospital
Observational
55
Zhengzhou
2025-02-01
Recruiting
The Study About the Identification of Treatable Traits of Severe Asthma and the Construction of Personalized Treatment System
NCT07136025Asthma
Beijing Chao Yang Hospital
Not applicable
200
Beijing, Guangzhou, Zhengzhou, Changsha, Shenyang, Shanghai, Taiyuan, Hangzhou
2025-02-01
Not yet open
A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple Myeloma
NCT06799676Newly Diagnosed Multiple Myeloma
Fuling Zhou
Phase 1/2
42
Zhengzhou, Wuhan, Xianning
2025-02
Not yet open
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
NCT06845241Relapsed or Refractory Non-Hodgkin Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 1/2
68
Fuzhou, Guangzhou, Zhengzhou, Nanchang, Tianjin, Kunming
2025-02
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
AstraZeneca
Phase 1/2
408
Beijing, Guangzhou, Jinan, Tianjin, Zhengzhou
2025-01-30
Recruiting
Clinical Trial of TQH3906 Capsules for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
NCT06754891Inflammatory Bowel Diseases
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1
135
Bengbu, Wuwei, Guangzhou, Huizhou, Harbin, Luoyang, Nanyang, Zhengzhou
2025-01-28
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
NCT06609005Advanced Metastatic Castration Resistant Prostate Cancer
Shenzhen Ionova Life Sciences Co., Ltd.
Phase 1/2
84
Beijing, Fuzhou, Foshan, Zhengzhou, Changsha, Nanjing, Nanchang, Shenyang
2025-01-23
Recruiting
A Study Evaluating the Safety and Immunogenicity of MVA Strain Monkeypox Attenuated Live Vaccine
NCT06771479Monkeypox
Shanghai Institute Of Biological Products
Phase 1
120
Zhengzhou
2025-01-22
Recruiting
A Trial of HRS-2189 in Combination With FluvastatinยฑHRS-6209, or HRS-8080ยฑHRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients
NCT06679036Advanced Unresectable or Metastatic Breast Cancer
Shandong Suncadia Medicine Co., Ltd.
Phase 1/2
300
Harbin, Zhengzhou
2025-01-21
Recruiting
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT06568939Non-Small Cell Lung Cancer
AbbVie
Phase 2
150
Beijing, Fuzhou, Nanning, Harbin, Zhengzhou, Wuhan, Nanchang, Xi'an
2025-01-20
Not yet open
Nanocrystalline Megestrol + Immunochemo As 1st-Line for ES-SCLC Cachexia
NCT06793228SCLC, Extensive Stage
Henan Cancer Hospital
Phase 2
250
Luoyang, Xinxiang, Zhengzhou
2025-01-15
Recruiting
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy With GenSci122 in Participants With Advanced Solid Tumors
NCT06772415Advanced Solid Tumor
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 1
163
Beijing, Zhengzhou, Changsha, Nanjing, Jinan, Shanghai, Tianjin
2025-01-08
Recruiting
A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune Thrombocytopenia
NCT07017725Chronic Immune Thrombocytopenia
CASI pharmaceuticals, Inc.
Phase 1/2
75
Tangshan, Zhengzhou, Nanchang, Jinan, Tianjin, Kunming
2025-01-03
Recruiting
HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma
NCT06737913Advanced Hepatocellular Carcinoma (HCC)
Sun Yat-sen University
Phase 2
76
Lanzhou, Guangzhou, Zhengzhou
2025-01-03
Not yet open
Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk Acute Myeloid Leukemia
NCT06643195AML
Institute of Hematology & Blood Diseases Hospital, China
Not applicable
358
Shijiazhuang, Zhengzhou, Jinan, Chengdu
2025-01-01
Recruiting
Bariatric Surgery Combined With GLP-1RA: A Multicenter Study.
NCT07732738Obesity
China-Japan Friendship Hospital
Not applicable
400
Xingtai, Zhengzhou, Baotou, Jinan, Datong, Kunming, Beijing
2025-01-01
Recruiting
Effects of Long-term Remote Ischemic Preconditioning on Clinical Outcome in Patients With Acute Myocardial Infarction
NCT07181356Acute Myocardial Infarction
Henan Institute of Cardiovascular Epidemiology
Not applicable
2,146
Zhengzhou
2025-01-01
Recruiting
Intracoronary rhTNK-tPA Versus Tirofiban in Patients With STEMI and High Thrombus Burden
NCT06769256ST-segment Elevation Myocardial Infarction (STEMI)
Henan Institute of Cardiovascular Epidemiology
Phase 4
300
Zhengzhou
2025-01-01
Recruiting
Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN
NCT07187908Primary/Secondary Prevention, High Risk for Febrile Neutropenia of Chemotherapy Regimens, Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in Febrile Neutropenia
Henan Cancer Hospital
Phase 2
1,076
Zhengzhou
2025-01-01
Rows per page Showing 301–400 of 921
Previous 2 3 4 5 6 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/zhengzhou?page=4

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 921 of those studies with a site in Zhengzhou.

How many clinical trials are recruiting in Zhengzhou?

553 of the 921 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 163 have not yet opened recruitment, 191 are active but closed to new participants, and 14 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.